hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06273163 id: STU-2023-1168 briefTitle: Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation overallStatus: RECRUITING date: 2024-03-05 date: 2024-12-31 date: 2024-12-31 date: 2024-02-22 date: 2024-03-08 name: University of Texas Southwestern Medical Center class: OTHER name: UT Southwestern Nutrition Obesity Research Center briefSummary: Longitudinal studies show there is a steep increase in weight regain in the first 3-4 months after stopping GLP-1 receptor agonist medications (GLP-1s) and most patients regain most of their weight within a year. Insurers now question the utility of GLP-1s for weight loss as they are hesitant to cover these costs long-term (\~$833 per person per month). Some patients would also prefer not to take these medications in perpetuity and are likely to struggle with lifelong adherence. These challenges present an opportunity to test alternative interventions, such as meal replacements and behavioral treatments, to support weight maintenance after successful weight loss with GLP-1s. This regimen would allow patients to benefit from significant weight loss in the first year of taking GLP-1s and use more cost effective and sustainable strategies for long-term maintenance. conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized repeated measures between-subjects design primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE maskingDescription: Complete masking is not feasible given the nature of the interventions - the program coordinator and participants will know if the participant receives home delivered medically tailored meals, a smart device application subscription, or usual care. The care provider will not be told the participants group assignment, but the participant may reveal it themselves in discussions with the provider. whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Medically tailored meals name: Noom® name: Usual care measure: Intervention Adherence measure: Intervention Satisfaction measure: Percent weight loss maintained measure: Diet quality measure: Incremental cost effective ratio (ICER) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UT Southwestern Medical Center status: RECRUITING city: Dallas state: Texas zip: 75390 country: United States name: Carolyn Haskins, MS role: CONTACT email: niche@utsouthwestern.edu name: Jessica ‪ Turcios, BS role: CONTACT email: niche@utsouthwestern.edu name: Kelseanna Hollis-Hansen, PhD, MPH role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06273150 id: 142048 briefTitle: Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study acronym: DRPLA NHBS overallStatus: RECRUITING date: 2022-05-01 date: 2026-04 date: 2026-04 date: 2024-02-22 date: 2024-02-22 name: University College, London class: OTHER name: University of North Carolina, Chapel Hill name: NYU Grossman School of Medicine briefSummary: DRPLA Natural History and Biomarkers Study (DRPLA NHBS) is a prospective observational study that will lay the foundation for clinical trials in DRPLA. The aims of this project are:
This project will allow for a better understanding of DRPLA and its course, and therefore allow for future clinical trials on this condition to be more precisely and effectively conducted. conditions: Dentatorubral-Pallidoluysian Atrophy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 225 type: ESTIMATED name: Positive genetic test for pathological expansion in ATN1 measure: Scale for the assessment and rating of ataxia (SARA) measure: Brain atrophy measure: Neurofilament plasma concentration (NfL) measure: Inventory of non-ataxia signs (INAS) measure: Upper limb function test AIM-S measure: Redenlab DRPLA specific speech battery measure: Clinical Assessment of Dysphagia in Neurodegeneration (CADN) measure: Tau plasma concentration measure: Glial fibrillary acidic protein (GFAP) concentration measure: Ubiquitin carboxyterminal hydrolase L1 (UCH-L1) concentration sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Grossman School of Medicine status: RECRUITING city: New York state: New York zip: 10017 country: United States name: Claire Miller role: CONTACT phone: 212-263-4838 email: Claire.Miller@nyulangone.org lat: 40.71427 lon: -74.00597 facility: University of North Carolina at Chapel Hill status: RECRUITING city: Chapel Hill state: North Carolina zip: 27599-7025 country: United States name: Yael Shiloh-Malawsky role: CONTACT phone: 919-966-2528 email: yaelm@neurology.unc.edu lat: 35.9132 lon: -79.05584 facility: University College London status: RECRUITING city: London zip: WC1N 3BG country: United Kingdom name: Paola Giunti role: CONTACT phone: +44 7899974923 email: p.giunti@ucl.ac.uk lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06273137 id: 2963 briefTitle: Positive Affect Treatment for Adolescents With Early Life Adversity acronym: PAT4ELA overallStatus: RECRUITING date: 2024-02-03 date: 2026-02-16 date: 2026-10-16 date: 2024-02-22 date: 2024-02-28 name: University of California, Irvine class: OTHER briefSummary: Youth exposed to early life adversity (ELA) are known to be at greater risk for depression and suicidality and account for almost half of the youth suffering from psychiatric diseases today. Youth exposed to ELA consistently report symptoms of anhedonia as well as dysregulated positive affect. The present project will test the efficacy of PAT in a sample of ELA-exposed adolescents in order to determine whether PAT increases positive affect, and subsequently symptoms of depression. For this pilot, the investigators will recruit 22 adolescents exposed to two or more childhood adversities (ACEs) who do not currently have major depressive disorder, and randomize them (1:1) to either participate in PAT or a waitlist control condition. At study enrollment, then 4-, 8, and 12-months thereafter the investigators will measure positive affect and depressive symptoms (including anhedonia). The results of this study will be used to inform whether PAT has the potential to prevent major depressive episodes among adversity-exposed youth. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Participants will be randomized 1:1 to either receive PAT upon enrollment or after a waitlist period. primaryPurpose: PREVENTION masking: NONE count: 22 type: ESTIMATED name: Positive affect treatment measure: Positive affect measure: depressive symptoms - total measure: depressive symptoms - anhedonia subscale measure: Systemic inflammation - C-reactive protein (CRP) measure: Inflammatory gene expression sex: ALL minimumAge: 12 Years maximumAge: 16 Years stdAges: CHILD facility: University of California Irvine status: RECRUITING city: Irvine state: California zip: 92617 country: United States name: Kate R Kuhlman role: CONTACT phone: 949-824-5574 email: krkuhl@uci.edu lat: 33.66946 lon: -117.82311 hasResults: False
nctId: NCT06273124 id: 150-1261-00 briefTitle: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes overallStatus: RECRUITING date: 2024-03-07 date: 2025-01-15 date: 2025-01-15 date: 2024-02-22 date: 2024-04-25 name: Tandem Diabetes Care, Inc. class: INDUSTRY name: Jaeb Center for Health Research briefSummary: The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).
nctId: NCT06273111 id: 73840 briefTitle: Topical Simvastatin for Treating Infantile Hemangioma acronym: TSTIH overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-07-31 date: 2025-12-31 date: 2024-02-22 date: 2024-02-22 name: Joyce Teng class: OTHER name: Stanford University briefSummary: This is a 24-week, open-label pilot study to evaluate the safety and preliminary efficacy of 5% simvastatin ointment in treating 12 children with superficial IH.
1.2 To evaluate the impact of 5% simvastatin ointment on quality of life using the IH-QoL questionnaire. conditions: Hemangioma Skin studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: 5% simvastatin ointment measure: Number of Participants with Treatment-Related Adverse Events measure: Percentage of participants achieved a 50% HAS reduction at week 12 compared to baseline measure: Percentage of participants achieved a 75% HAS reduction from baseline by the end of the study (week 24) compared to baseline. measure: Percentage of targeted hemangiomas with complete or nearly complete resolution (IGA 0 or 1), defined as a minimal degree of telangiectasia, skin thickening, and no definitive palpable cutaneous texture changes. measure: Percentage of targeted hemangiomas that are stabilized (no noticeable change to baseline) or continue to progress. measure: Percentage of participants with a significant improvement in quality-of-life, defined as > 50% reduction in the IH-QoL questionnaire score from baseline to week 24. sex: ALL minimumAge: 3 Months maximumAge: 5 Years stdAges: CHILD facility: Stanford University city: Palo Alto state: California zip: 94304 country: United States name: Ramrada Lekwuttikarn, MD role: CONTACT phone: 650-313-8207 email: ramrada1@stanford.edu name: Thomas Buschbacher role: CONTACT phone: 352-278-7603 email: tbusch@stanford.edu lat: 37.44188 lon: -122.14302 hasResults: False
nctId: NCT06273098 id: 73162 briefTitle: School-Based Bladder Health Intervention overallStatus: WITHDRAWN date: 2028-01-01 date: 2033-12-31 date: 2033-12-31 date: 2024-02-22 date: 2024-04-24 name: Stanford University class: OTHER briefSummary: The aim of this study is to promote healthy bladder behaviors among school children. We hypothesize that a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies can promote healthy bladder behaviors among school children. conditions: Urinary Dysfunction conditions: Lower Urinary Tract Symptoms conditions: Urinary Tract Infections conditions: Urinary Tract Infections in Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 0 type: ACTUAL name: Bladder Health Education measure: Bathroom use measure: Symptom score measure: Urine volume sex: ALL minimumAge: 5 Years maximumAge: 10 Years stdAges: CHILD facility: Stanford Hospital and Clinics city: Palo Alto state: California zip: 94304 country: United States lat: 37.44188 lon: -122.14302 hasResults: False
nctId: NCT06273085 id: MOD00016877 briefTitle: Intensive Education Versus Usual Education of Patients for Improving Guideline Directed Medical Therapy (GDMT) Prescription in Heart Failure With Reduced Ejection Fraction overallStatus: RECRUITING date: 2024-02-01 date: 2025-02 date: 2025-02 date: 2024-02-22 date: 2024-02-26 name: Medstar Health Baltimore class: OTHER briefSummary: The goal of this randomized clinical trial is to test the effect of patient education on extent of use of guideline directed medical treatment (GDMT) of heart failure with reduced ejection fraction. The main question that our study aims to answer is if patient education can improve the adherence to GDMT in heart failure with reduced ejection fraction. Participants will receive educations about GDMT benefits in 1,3 and 5 months after discharge from hospital. conditions: Heart Failure conditions: Patient Acceptance of Health Care studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 500 type: ESTIMATED name: Patient education measure: Change in GDMT score measure: Heart Failure hospitalization measure: cardiovascular death/Left Ventricular Assist Device implantation/Cardiac Transplant measure: Number of GDMT classes of medications in use sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medstar Union Memorial Hospital status: RECRUITING city: Baltimore state: Maryland zip: 21218 country: United States name: Ahmad Amin, MD role: CONTACT phone: 401-533-0696 email: ahmad.amin@medstar.net lat: 39.29038 lon: -76.61219 facility: Medstar Harbor Hospital status: RECRUITING city: Baltimore state: Maryland zip: 21225 country: United States name: Sumanth Bandaru, MBBS role: CONTACT phone: 646-240-5289 email: sumanthkumar.bandaru@medstar.net lat: 39.29038 lon: -76.61219 facility: Medstar Franklin Medical Center status: RECRUITING city: Baltimore state: Maryland zip: 21237 country: United States name: Anup Agarwal, MD role: CONTACT phone: 505-620-7815 email: anup.agarwal@medstar.net lat: 39.29038 lon: -76.61219 facility: Medstar Good Samaritan Hospital status: RECRUITING city: Baltimore state: Maryland zip: 21239 country: United States name: Sumanth Bandaru, MBBS role: CONTACT phone: 646-240-5289 email: sumanthkumar.bandaru@medstar.net lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06273072 id: IRB00409080 id: R34HL166438-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/R34HL166438-01A1 briefTitle: Metformin IN Asthma for Overweight and Obese Individuals (MINA) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-09-30 date: 2028-12-31 date: 2024-02-22 date: 2024-03-15 name: Johns Hopkins University class: OTHER name: Baylor College of Medicine name: National Heart, Lung, and Blood Institute (NHLBI) name: Temple University briefSummary: This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy. conditions: Asthma conditions: Asthma Chronic conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Metformin hydrochloride extended-release tablets name: Visually identical placebo Metformin hydrochloride extended-release tablets measure: Number of completed telemedicine visits measure: Adherence to study drug measure: Retention rate measure: Asthma control as assessed by the Asthma Control Test (ACT) score measure: Change in Asthma exacerbations rate measure: Pre-bronchodilator lung function measure: Fractional exhaled nitric oxide (FeNO) measure: Airways hyperresponsiveness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06273059 id: 22-07-0717 briefTitle: Genomic Study of Young-Onset Diabetes Mellitus overallStatus: RECRUITING date: 2022-09-12 date: 2024-12-12 date: 2024-12-12 date: 2024-02-22 date: 2024-02-22 name: Indonesia University class: OTHER briefSummary: Diabetes Mellitus (DM) has been a major contributor to health burden in Indonesia and currently its burden still continues to rise. This is a result of increasing DM prevalence in the country as well as high rates of chronic complications from DM. Findings in Indonesia show that there is a high proportion of young people with diabetes, and also a high risk of therapeutic failure and complications from DM occurring in the younger population.
This study is a pilot project aimed to initiate genomic research in young-onset DM patients in Indonesia. In the short term, this study aims to identify genetic variants that may be able to increase diagnostic accuracy of the young-onset DM spectrum. In the long term, this study aims to identify new genetic variants of young-onset DM. The study also aims to identify genetic variants associated with risks of chronic complications. conditions: Genomic conditions: Diabetes Mellitus conditions: MODY studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 1000 type: ESTIMATED measure: The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia. measure: To describe the proportion of MODY in young-onset DM measure: To describe genetic variation of MODY in Indonesia. measure: To describe genetic variation in young-onset DM with diabetic complications in various systems: sex: ALL minimumAge: 8 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Cipto Mangunkusumo Hospital status: RECRUITING city: Jakarta Pusat state: DKI Jakarta zip: 10430 country: Indonesia role: CONTACT phone: 1 500 135 lat: -6.1818 lon: 106.8223 hasResults: False
nctId: NCT06273046 id: PR(AG)614/2023 briefTitle: Treatment of Fecal Incontinence and Functional Defecation Disorders Using Non-instrumental Biofeedback overallStatus: RECRUITING date: 2024-04-19 date: 2025-04-28 date: 2025-12-31 date: 2024-02-22 date: 2024-04-25 name: Hospital Universitari Vall d'Hebron Research Institute class: OTHER briefSummary: Background. Rehabilitation and re-education using instrumental anorectal biofeedback are the main treatment of anorectal functional disorders producing incontinence and outlet obstructed defecation. These treatments imply intubation of patient and several sessions of treatment leading to high consumption of resources and costs.
Intervention. In separate studies (incontinence and dyssynergic defecation) patients will be randomized into biofeedback and placebo groups. One session of either biofeedback or placebo intervention will be performed at the beginning of the intervention period and patients will be instructed to performed the assigned daily treatment at home. A visit for outcome assessment will be performed at 3 months in incontinence study and at 4 weeks in the dyssinergic defecation study. In addition, in the incontinence study a phone call will be performed after 6 months of the beginning of the study to evaluate treatment outcome.
Placebo: a pill of placebo containing 0.3 g glucose will be administered every day at home. conditions: Fecal Incontinence conditions: Outlet Dysfunction Constipation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 96 type: ESTIMATED name: Biofeedback name: Placebo measure: Fecal incontinence study: Number of anal leaks measure: Dyssinergic defecation study: Number of bowel movements measure: Incontinence study: Wexner scale measure: Incontinence study: Quality of life measure: Incontinence study: anxiety and depression measure: Incontinence study: Anal sphincter function measure: Dyssinergic defecation study: sensation of outlet obstructed evacuation measure: Dyssinergic defecation study: Wexner scale measure: Dyssinergic defecation study: Quality of life measure: Dyssinergic defecation study: anxiety and depression measure: Dyssinergic defecation study: defecatory maneuvers sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Vall d'Hebron status: RECRUITING city: Barcelona country: Spain name: Jordi Serra, MD role: CONTACT lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06273033 id: CONCORDE briefTitle: Implementation of Contemporary Coronary CT Angiography in Clinical Practice acronym: CONCORDE overallStatus: RECRUITING date: 2023-10-10 date: 2024-10 date: 2025-01 date: 2024-02-22 date: 2024-03-01 name: Humanitas Hospital, Italy class: OTHER briefSummary: Coronary CT angiography (CCTA) has been recognized as the first-line diagnostic test for most patients with suspected coronary syndrome, often acting as a gatekeeper for invasive coronary angiography. It is therefore pivotal to understand instances of discrepancies that are encountered in clinical practice. Moreover, most of the literature on this topic relies on obsolete machines or definitions of coronary artery stenosis that cannot be defined as severe.
The investigators aim 1) to report the real word data on the performance of last-generation CCTA in identifying obstructive coronary artery disease (also considering different thresholds of stenosis, i.e., moderate or severe) and 2) to identify predictors of discrepancies. conditions: Coronary Artery Disease of Significant Bypass Graft conditions: Coronary Syndrome conditions: Coronary Arteriosclerosis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥70% in a patient with suspected CAD. measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥50% in a patient with suspected CAD. measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥70% in a vessel of a patient with suspected CAD measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥50% in a vessel of a patient with suspected CAD sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Humanitas Research Hospital status: RECRUITING city: Rozzano state: Milano zip: 20089 country: Italy name: Carlo Andrea Pivato, MD role: CONTACT phone: +39 02 8224 7235 email: carlo.pivato@humanitas.it lat: 45.38193 lon: 9.1559 hasResults: False
nctId: NCT06273020 id: MI22-00013 briefTitle: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke overallStatus: RECRUITING date: 2022-11-17 date: 2024-11 date: 2024-12 date: 2024-02-22 date: 2024-02-22 name: Hospital Universitario Dr. Jose E. Gonzalez class: OTHER name: Ever Neuro Pharma GmbH briefSummary: A prospective, single-center study would be carried out in the Neurology Department of the University Hospital "Dr. José Eleuterio González" in order to analyze the effect of cerebrolysin on the blood-brain-barrier in patients with ischemic stroke with personal history of type-2 diabetes conditions: Ischemic Stroke, Acute conditions: Diabetes Mellitus, Type 2 conditions: Blood Brain Barrier studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: There are 3 groups in this clinical trial
Group 3: 20 patients that they were not candidates to receive IVT (out of therapeutic window) but agreed to receive cerebrolysin (randomization not used) primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Cerebrolysin name: Brain-MRI with contrast after 10-14 days of cerebrolysin measure: Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery measure: Comparison of clinical severity, using NIH Stroke Scale in patients with and withouth cerebrolysin measure: Comparison of functional prognosis, using modified Rankin scale in patients with and withouth cerebrolysin measure: Comparison of cognitive impairment, using Montreal Cognitive Assessment in patients with and withouth cerebrolysin sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Servicio de Neurología del Hospital Universitario "Dr.José E. González" status: RECRUITING city: Nuevo León state: Monterrey zip: 64020 country: Mexico name: Servicio F de Neurología del Hospital Universitario "Dr.José E. González" role: CONTACT phone: +528183591111 email: neurologiahu.posgrado@gmail.com name: José C Becerra-Cruz, M.D. role: CONTACT phone: +522324393970 email: becerracruz@hotmail.com hasResults: False
nctId: NCT06273007 id: EFP_2023_02_19 briefTitle: Improving Intrapartum Care for Saving Life at Birth in Ethiopia Through PartoMa Approach acronym: PartoMa-Eth overallStatus: RECRUITING date: 2023-06-01 date: 2025-12-31 date: 2027-12-31 date: 2024-02-22 date: 2024-02-22 name: Haramaya Unversity class: OTHER name: University of Copenhagen name: Leiden University Medical Center name: Laerdal Foundation briefSummary: Overall Objective